Patterns of Failure and Prognostic Factors in XXXX Treated with Radiotherapy.

@entity1 @entity5 @entity1138 @entity900 @entity177 @entity1442 @entity3 @entity1487
PURPOSE: To analyze the patterns of failure and prognostic factors affecting the local control and survivals in @entity5 treated with definitive radiotherapy, and to find the most effective treatment modality. MATERIALS AND METHODS: Thirty consecutive @entity1 , with primary @entity5 of the anal canal, were treated using radiotherapy, both with and without @entity1487 based concurrent chemotherapy. According to the AJCC @entity5 stage, six @entity1 hadwere stage I, 11 had stage II, 2 had stage IIIA, and 11 had stage IIIB @entity5 . The median radiation dose was 45 Gy (30-72 Gy), and with 23 @entity1 receivinged concurrent chemotherapy ( @entity1487 and @entity1138 in 12 @entity1 , @entity1487 and @entity900 in 7, and other drugs in 4). The Mmedian follow up period was 43 months, (ranginge, from 8- to 99 months). RESULTS: Among the 1630 @entity1 who16 were treated without surgical resection beforeprior to the radiotherapy, and a complete remission was observed in 12 @entity1 (75%), a partial remission in 3 (19%), and a local progression in the other one @entity1 . The @entity177 , including persistent disease, were observed in 10 (33%), and the @entity1 with higher T-stages (T3-4) had higher rates of local failure rates (T1-2, 21% vs. T3-4, 72%, p=0.03). Distant @entity3 were found in 4 @entity1 (13%). The five year survival and disease free survival rates were 64% and 53%, respectively. The factors which affectinged the 5 year local relapse free survival were T-stage (74.9% in T1-2 vs. 28.6% in T3-4, p=0.01), and the existence of a gross @entity5 beforeprior to radiotherapy (84.6%, no residual vs. 45.1% with residual, p=0.03). CONCLUSION: A Llocal recurrence was the major failure pattern in @entity5 , and the factors affecting a local failure were the T-stage and @entity5 volume beforeprior to radiotherapy. A Rradiation dose around 45 Gy was sufficient to control @entity5 of the @entity5 , but a higher dose should be considered for with more @entity1442 .
